Professor Clive Taylor attended medical school at the University of Cambridge and completed his doctoral studies in Immunology at Oxford prior to accepting an appointment at University of Southern California where he served as Chair of the Department of Pathology and Laboratory Medicine for 25 years, and Dean for Educational Affairs for 10 years. Dr. Taylor is a Fellow of the Royal College of Pathologists (U.K), a Diplomat of the American Board of Pathology, a Member of the Royal College of Physicians (Ireland), and the Royal Society of Medicine. He was elected President of the U.S. Association of Pathology Chairs from 1996 – 1999, President of the U.S. Biological Stain Commission from 1994-1998 and Chaired an FDA Advisory Panel for Diagnostic Devices and Radiology until 2007.
Professor Taylor’s primary research relates to advanced methods of diagnosis and treatment of cancer, by immunologic and molecular methods, with emphasis upon standardization and quantification. He has published more than 400 papers plus 20 books. Currently he is Editor in Chief of Applied Immunohistochemistry and Molecular Morphology.
Dr. David Rimm, is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is a member of the Executive Team in Pathology and serves as the Director of Tranlational Pathology. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer. He is currently supported by 9 grants from both public and private sources. He serves as a reviewer for the NIH and was a charter member of the Cancer Biomarkers Study Section. He is an editorial board member for 7 pathology journals and a member of the pathology committee for TransALLTO and TEACH (cooperative groups or therapeutic clinical trials). He is an author of over 275 peer-reviewed papers and 8 patents and was the scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.
Dr. Montalto is a research and development leader with a broad range of experience at the executive level including R&D, clinical, regulatory, medical and scientific affairs. He is currently the Executive Director and Head of Translational Pathology and Biomarker Sciences in Translational Medicine at Bristol-Myer Squibb. In this role he leads genomics, genetics, flow cytometry, histo-chemistry and pathology laboratories in support of global clinical trials, exploratory biomarker research and companion diagnostics. Prior to this role, Dr. Montalto was a co-founder and executive of Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products through GE Healthcare. He has patented and published on novel digital pathology-based multiplexing technology (MultiOmyx™, Clarient/Neogenomics) for oncology biomarker discovery. He has designed and led global clinical trials for digital pathology devices and served as chair of the regulatory taskforce of the Digital Pathology Association (DPA). He currently serves as an executive member of the Board of Directors of the DPA as President-elect and Treasurer. He has served as a member of NIH study sections for in vivo molecular imaging centers. Dr. Montalto earned his PhD in tumor biology from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Women’s Hospital, Harvard Medical School.
Dr. Jiaoti Huang earned his medical degree from Anhui Medical University in 1983 and a Master’s degree in Pharmacology from the Institute of Radiation Medicine in Beijing in 1986. He earned his PhD from New York University School of Medicine (1987-1990). He was a Leukemia Society of America Postdoctoral Fellow at NYU and Yale University. He did residency training in pathology at NYU School of Medicine and a fellowship in Oncologic Surgical Pathology at Memorial Sloan-Kettering Cancer Center. He became an assistant professor at the University of Rochester in July 2000 and rose to the rank of full professor in 2007. Dr. Huang moved to UCLA in 2008 and came to Duke University at the beginning of 2016. He is currently Professor and Chairman of Department of Pathology, as well as Professor of Pharmacology and Cancer Biology at Duke University. He is also a member of the Duke Cancer Institute.
Dr. Huang is an expert surgical pathologist and prostate cancer researcher. His clinical expertise is in the pathologic diagnosis of genitourinary tumors. His research laboratory investigates the molecular mechanisms, biomarkers, imaging and novel therapies for advanced prostate cancer. His research laboratory is a leader in studying neuroendocrine differentiation of prostate cancer and molecular pathogenesis of prostatic small cell neuroendocrine carcinoma. Dr. Huang has published 200 research papers, review articles and book chapters. His research has been supported by the National Institutes of Health, Department of Defense Prostate Cancer Research Program, American Cancer Society, Prostate Cancer Foundation, and Stand Up to Cancer.
Abul K. Abbas received his medical degree in India, completed training in Pathology at Harvard and joined the faculty at Harvard Medical School and the Brigham and Women’s Hospital, where he rose to become Professor of Pathology and Head of the Immunology Research Division. In 1999, after twenty years on the Harvard faculty, he moved to the University of California at San Francisco as Professor and Chairman of the Department of Pathology. Dr. Abbas has received several honors, including election to the Institute of Medicine of the National Academy of Sciences, election as a Fellow of the American Academy of Arts and Sciences, and the Rous-Whipple Award and Robbins Educator Award of the American Society of Investigative Pathology. He has served as one of the founding Editors and Associate Editor of Immunity, Associate Editor and Section Editor for The Journal of Immunology, Associate Editor of Cell, Consulting Editor of The Journal of Clinical Investigation, and founding Editor of the Annual Review of Pathology: Mechanisms of Disease. From 2011-2013, he was the President of the Federation of Clinical Immunology Societies (FOCIS).
Dr. Abbas’ research interests are in Immunology, with a focus on the control of immune responses and the causes of autoimmunity. His laboratory has used experimental models to analyze the generation and maintenance of regulatory T cells. He has published over 200 peer-reviewed papers and invited reviews, and is the author of four widely read textbooks, two in Immunology and two in Pathology. He has taught Immunology at Harvard Medical School and UCSF, and has organized and conducted Immunology courses worldwide.
Dr. Gown received his MD from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY in 1975, and then completed his Pathology Residency as well as Pathology Fellowship training at the University of Washington, Seattle, the latter under the aegis of Dr. Earl Benditt. Dr. Gown rose through the ranks to full Professor of Pathology and served as attending pathologist at the University of Washington Medical Center, where he developed and directed the immunohistochemistry (IHC) laboratory. In 1997, Dr. Gown left the University of Washington to found PhenoPath, which has grown to become an internationally renowned specialty pathology reference laboratory. Currently, Medical Director and Chief Pathologist at PhenoPath, Dr. Gown is a pathologist-scientist recognized as one of the world’s leading experts in the diagnostic and research applications of IHC. He has developed numerous clinically important monoclonal antibodies employed in IHC laboratories around the world (HMB-45, OSCAR, etc.). Dr. Gown is a member of the editorial boards of many of the major pathology journals. He is a Clinical Professor of Pathology at the University of British Columbia, Vancouver, BC, and an Affiliate Investigator in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA. Dr. Gown continues to be at the forefront of clinical investigative studies employing IHC and other modalities with over 300 peer-reviewed publications and as a frequent presenter at national and international conferences.